When seropositivity for anti-Np is used as the indicator for COVID-19 detection, there is an increasing trend in EBV reactivation determined through detection of antibodies against EA-D and VCA in COVID-19 positivity samples. 9/38 (23.7%) patient samples were negative for anti-Np antibodies but had antibodies against either EA-D or VCA, whereas 16/55 (29.1%) patient samples were positive for anti-Np antibodies and had antibodies against either VCA or EA-D.
← all excerpts
Incidence of Epstein-Barr virus reactivation is elevated in COVID-19 patients.
1
—
—